In Section C, contributors will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will get ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or the contributors are unable to tolerate the study drugs. Celastrol was identified for a Myb inhibitor that suppressed C/EBPβ action and repressed https://abbv-744safetyandsideeffe24578.blogsuperapp.com/32586647/abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-options